Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms.

Guglielmelli P, Pacilli A, Coltro G, Mannelli F, Mannelli L, Contini E, Rotunno G, Bartalucci N, Fiaccabrino S, Sordi B, Loscocco GG, Paoli C, Vannucchi AM.

Am J Hematol. 2020 Jan;95(1):E23-E26. doi: 10.1002/ajh.25668. Epub 2019 Nov 12. No abstract available.

PMID:
31659782
2.

Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing.

Bartalucci N, Romagnoli S, Contini E, Marseglia G, Magi A, Guglielmelli P, Pelo E, Vannucchi AM.

Clin Chem. 2019 Dec;65(12):1605-1608. doi: 10.1373/clinchem.2019.310805. Epub 2019 Oct 23. No abstract available.

PMID:
31645339
3.

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.

Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, Pennucci V, Ruberti S, Rossi C, Rontauroli S, Enzo E, Calabresi L, Balliu M, Mannarelli C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.

Sci Rep. 2019 Jul 22;9(1):10558. doi: 10.1038/s41598-019-46843-z.

4.

NanoR: A user-friendly R package to analyze and compare nanopore sequencing data.

Bolognini D, Bartalucci N, Mingrino A, Vannucchi AM, Magi A.

PLoS One. 2019 May 9;14(5):e0216471. doi: 10.1371/journal.pone.0216471. eCollection 2019.

5.

Decarbonylation of phenylacetic acids by high valent transition metal halides.

Bartalucci N, Marchetti F, Zacchini S, Pampaloni G.

Dalton Trans. 2019 Apr 23;48(17):5725-5734. doi: 10.1039/c9dt00551j.

PMID:
30969293
6.

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data.

Magi A, Bolognini D, Bartalucci N, Mingrino A, Semeraro R, Giovannini L, Bonifacio S, Parrini D, Pelo E, Mannelli F, Guglielmelli P, Maria Vannucchi A.

Bioinformatics. 2019 Nov 1;35(21):4213-4221. doi: 10.1093/bioinformatics/btz241.

PMID:
30949684
7.

Straightforward formation of carbocations from tertiary carboxylic acids via CO release at room temperature.

Bartalucci N, Bortoluzzi M, Zacchini S, Pampaloni G, Marchetti F.

Dalton Trans. 2019 Feb 7;48(5):1574-1577. doi: 10.1039/c8dt04416c. Epub 2018 Dec 7.

PMID:
30525172
8.

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P.

Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x.

9.

Ubiquity of cis-Halide → Isocyanide Direct Interligand Interaction in Organometallic Complexes.

Bartalucci N, Belpassi L, Marchetti F, Pampaloni G, Zacchini S, Ciancaleoni G.

Inorg Chem. 2018 Dec 3;57(23):14554-14563. doi: 10.1021/acs.inorgchem.8b02088. Epub 2018 Nov 15.

PMID:
30430836
10.

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.

Rossi C, Zini R, Rontauroli S, Ruberti S, Prudente Z, Barbieri G, Bianchi E, Salati S, Genovese E, Bartalucci N, Guglielmelli P, Tagliafico E, Rosti V, Barosi G, Vannucchi AM, Manfredini R; AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) investigators.

Mol Oncol. 2018 Dec;12(12):2102-2123. doi: 10.1002/1878-0261.12387. Epub 2018 Nov 16.

11.

Familial dominant epilepsy and mild pachygyria associated with a constitutional LIS1 mutation.

De Vita D, Mei D, Rutigliano D, Bartalucci N, Cinnante CM, Parrini E, Dilena R, Guerrini R.

Am J Med Genet A. 2018 Dec;176(12):2808-2812. doi: 10.1002/ajmg.a.40503. Epub 2018 Aug 25.

PMID:
30144370
12.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

13.

Stable coordination complexes of α-diimines with Nb(v) and Ta(v) halides.

Bartalucci N, Bortoluzzi M, Pampaloni G, Pinzino C, Zacchini S, Marchetti F.

Dalton Trans. 2018 Mar 6;47(10):3346-3355. doi: 10.1039/c8dt00122g.

PMID:
29423490
14.

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

Salati S, Prudente Z, Genovese E, Pennucci V, Rontauroli S, Bartalucci N, Mannarelli C, Ruberti S, Zini R, Rossi C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.

Stem Cells Dev. 2017 Dec 19. doi: 10.1089/scd.2017.0137. [Epub ahead of print]

PMID:
29258411
15.

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, Annunziato F, Guglielmelli P, Vannucchi AM.

Oncotarget. 2017 May 22;8(57):96710-96724. doi: 10.18632/oncotarget.18073. eCollection 2017 Nov 14.

16.

Allowing the direct interaction of N-aryl α-diimines with a high valent metal chloride: one-pot WCl6-promoted formation of quinoxalinium salts.

Bartalucci N, Bortoluzzi M, Funaioli T, Marchetti F, Pampaloni G, Zacchini S.

Dalton Trans. 2017 Oct 3;46(38):12780-12784. doi: 10.1039/c7dt03226a.

PMID:
28932841
17.

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.

Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.

18.

Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.

Erba BG, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, Villeval JL, Vannucchi AM, Barosi G, Balduini A, Dejana E.

Am J Pathol. 2017 Aug;187(8):1879-1892. doi: 10.1016/j.ajpath.2017.04.006.

19.

Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic-Acid-Modified Pyridine and Triphenylphosphine Ligands.

Agonigi G, Riedel T, Zacchini S, Păunescu E, Pampaloni G, Bartalucci N, Dyson PJ, Marchetti F.

Inorg Chem. 2015 Jul 6;54(13):6504-12. doi: 10.1021/acs.inorgchem.5b00802. Epub 2015 Jun 15.

PMID:
26073654
20.

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.

Pardanani A, Tefferi A, Guglielmelli P, Bogani C, Bartalucci N, Rodríguez J, Extremera S, Pérez I, Alfaro V, Vannucchi AM.

Blood Cancer J. 2015 Mar 13;5:e286. doi: 10.1038/bcj.2015.5.

21.

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.

Guglielmelli P, Bartalucci N, Rotunno G, Vannucchi AM.

Expert Rev Hematol. 2014 Aug;7(4):423-5. doi: 10.1586/17474086.2014.920250. Epub 2014 May 22.

PMID:
24849893
22.

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.

Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, Mannarelli C, Pacilli A, Calabresi L, Fjerza R, Pieri L, Bosi A, Manfredini R, Guglielmelli P.

Leukemia. 2014 Sep;28(9):1811-8. doi: 10.1038/leu.2014.100. Epub 2014 Mar 12.

23.

Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

Bartalucci N, Guglielmelli P, Vannucchi AM.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S307-9. doi: 10.1016/j.clml.2013.07.011. Review.

PMID:
24290217
24.

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval JL, Vannucchi AM.

J Cell Mol Med. 2013 Nov;17(11):1385-96. doi: 10.1111/jcmm.12162. Epub 2013 Nov 17.

25.

Preclinical models for drug selection in myeloproliferative neoplasms.

Bartalucci N, Bogani C, Vannucchi AM.

Curr Hematol Malig Rep. 2013 Dec;8(4):317-24. doi: 10.1007/s11899-013-0182-1. Review.

PMID:
24146202
26.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.

27.

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators.

Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1.

28.

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi AM.

Haematologica. 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. Epub 2010 Apr 23. No abstract available.

29.

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, Bosi A, Vannucchi AM.

Haematologica. 2009 Nov;94(11):1537-45. doi: 10.3324/haematol.2009.007047. Epub 2009 Jul 16.

30.

No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia.

Ponziani V, Mannelli F, Bartalucci N, Gianfaldoni G, Leoni F, Antonioli E, Guglielmelli P, Ciolli S, Bosi A, Vannucchi AM.

Leukemia. 2008 Mar;22(3):669-71. Epub 2007 Sep 6. No abstract available.

PMID:
17805324

Supplemental Content

Loading ...
Support Center